Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received multiple price target raises following its quarterly earnings report. Late ...

Insurance Analyst Shannon Martin joins the FOX 35 News team to talk about the biggest changes in Florida's insurance ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Stocks started rising as the day unfolded with Fed Chair Jerome Powell reinforcing that interest rates remain in a "good ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...